Novavax, Inc. (NASDAQ:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced that it has priced an underwritten public offering of 25 million shares of common stock at a price to the public of $4.00 per share for gross proceeds of approximately $100 million. Novavax, Inc. (NASDAQ:NVAX) weekly performance is -11.57%. On last trading day company shares ended up $4.16. Analysts mean target price for the company is $11.00. Novavax, Inc. (NASDAQ:NVAX) distance from 50-day simple moving average (SMA50) is -3.57%.
On May 20, 2014, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) delivered to Ono a notice of termination of their 2008 License Agreement under Section 10.2.1 based on Ono’s material breach of the Agreement. Under the terms of the Agreement, the termination is effective immediately. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) shares fell -6.49% in last trading session and ended the day on $3.46. PGNX gross Margin is 92.00% and its return on assets is -32.20%.Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) quarterly performance is -26.38%.
Receptos Inc. (NASDAQ:RCPT) Director Kristina Burow sold 153,698 shares of the company’s stock in a transaction that occurred on Thursday, May 29th. The stock was sold at an average price of $29.74, for a total value of $4,570,978.52. Following the transaction, the director now directly owns 13,333 shares in the company, valued at approximately $396,523. Receptos Inc. (NASDAQ:RCPT) shares moved down -5.69% in last trading session and was closed at $26.00, while trading in range of $25.61 – $27.81. Receptos Inc. (NASDAQ:RCPT) year to date (YTD) performance is -10.31%.
Hyperion Therapeutics, Inc. (NASDAQ:HPTX) on 3 June announced that the validation period is complete for its New Drug Submission (NDS) to Health Canada for RAVICTI (glycerol phenylbutyrate) Oral Liquid for the treatment of urea cycle disorders (UCDs), and that the RAVICTI NDS was granted Priority Review. Hyperion Therapeutics Inc. (NASDAQ:HPTX) ended the last trading day at $26.95. Company weekly volatility is calculated as 6.13% and price to cash ratio as 4.52.Hyperion Therapeutics Inc. (NASDAQ:HPTX) showed a negative weekly performance of -7.93%.
Seattle’s NanoString Technologies (NASDAQ:NSTG) announced on 3 June a collaboration with Celgene (NASDAQ:CELG) to build a companion diagnostic for the use of Celgene’s lenalidomide (Revlimid) in the treatment of diffuse large B-Cell lymphoma. NanoString receives $5.75 million upfront, and it could also earn $17 million in potential development and regulatory milestones and $22.25 million in potential commercial milestones. NanoString Technologies Inc. (NASDAQ:NSTG) weekly performance is 2.69%. On last trading day company shares ended up $15.29. Analysts mean target price for the company is $23.00. NanoString Technologies Inc. (NASDAQ:NSTG) distance from 50-day simple moving average (SMA50) is -6.34%.